Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Myovant Sciences Ltd (MYOV)

NYSE
Currency in USD
Disclaimer
26.98
0.00(0.00%)
Closed

MYOV Price Commentary

1. Great fundamentals a) Great Product - 2 approved life saving/changing blockbusters and another pending. Featured in New England of Medicine which is a big deal. Not going into technical but many doctors and client attested to the benefits and the increasing scripts speaks of itself. Adoption rate and reviews are good. PDUFA for 3rd blockbuster in May 22. partial clinical hold for SERENE trial is recently removed by FDA b) strong financials - huge cash runway of $6b+ cash for a $1.4b-1.5b market capital company with incoming streams of income from tiered payments and commercialising sales of 2 great products. Great leaps in price to sales ratio (value) and also enterprise value to EBITA (growth) Q to Q. Sales going strong and positive affirmation on drugs. Estimated Q1 Earnings is 3983% YOY c) Experienced Pfizer commercialising the above drugs.. acknowledging the value with 4.2b tiered payment.. Pfizer taking this on also speaks vol
Sumitomo is forced to offset its patent cliff in 2023, making Myovant a hot buyout target. The buyout speculation peaked, when Sumitomo announced the acquisition of Urovant Sciences. With the acquisition of Urovant, Myovant is the only out of 5 vant companies not wholly-owned by Sumitomo.
Looking at MYOV… potential buyout with 2 drugs approved and 1 upcoming… commercialisation undertaken by Pfizer…. All stars aligned… heavily undervalued
Buy out the float and force a buyout from the bullies
underdog taken down by giants through manipulation. 2 blockbuster drugs commercialising and cash on hand… just to buy up the Low float and it’s up up be away…
why price down after fda approved
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.